REFERENCES
- Schafer A I. Thrombocytosis and thrombocythemia. Blood Rev. 2000; 15: 159–166
- Hsu H C, Tsai W H, Jiang M L. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med. 1999; 134: 392–397
- Verbeek W, Faulhaber M, Griesinger F, et al. Measurement of thrombopoietic levels: clinical and biological relationships. Curr Opin Hematol. 2000; 7: 143–149
- Pearson T C. Primary thrombocythaemia: diagnosis and management. Br J Haematol. 1991; 78: 145–148
- Spivak J L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol. 2004; 41(Suppl 2)1–5
- Dror Y, Blanchette V S. Essential thrombocythaemia in children. Br J Haematol. 1999; 107: 691–698
- Chen H L, Chiou S S, Sheen J M, et al. Thrombocytosis in children at one medical center of southern Taiwan. Acta Paediatr Taiwan 1999; 40: 309–313
- Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol. 2000; 110: 751
- Tsimberidou A M, Giles F J. Essential thrombocythemia (ET): moving from palliation to cure. Hematology 2002; 7: 315–323
- Stutor AHx˙. Pediatric Hematology 2nd ed. Churchill Livingston. 1999; 455–464
- Sutor A H. Thrombocytosis in childhood. Semin Thromb Hemost. 1995; 21: 330–339
- Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol. 2000; 110: 751
- Osgood E E. Polycythemia vera: age relationships and survival. Blood 1965; 26: 243–256
- Cario H. Childhood polycythemias/erythrocytosis: classification, diagnosis, clinical presentation, and treatment. Ann Hematol. 2005; 84: 137–145
- Ghilardi N, Wiestner A, Kikuchi M, et al. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol. 1999; 107: 310–316
- Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004; 103: 4198–4200
- Levine R L, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397
- Randi M L, Putti M C, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006; 108: 3600–3602
- Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007; 25: 1048–1053
- Michiels J J, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost. 1997; 23: 339–347
- Martini M, Teofili L, Larocca L M. Overexpression of PRV-1 gene in polycythemia rubra vera and essential thrombocythemia. Methods Mol Med. 2006; 125: 265–273
- Goerttler P S, Setimle C, Marz E, et al. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005; 106: 2862–2864
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097